Oncology CAR-T has a geography problem The gap between what CAR-T can do and who can actually get it is the defining challenge of this field right now.
Oncology ASCO 2026: A potential functional cure in endometrial cancer... For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep.
Oncology Citius’ Leonard Mazur talks targeted immune therapy for CTCL Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals, discusses the launch of its first FDA-approved drug, Lymphir, for CTCL.
Oncology ASCO 2026 reshapes oncology trial design The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly mo
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Oncology Liquid biopsy and the future of tumour-agnostic treatments Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.
Oncology Dr Michael Bauer on Quantro’s mission to drug the “undruggab... Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
